IMTX immatics.com: Enterprise Value to EBITDA Ratio
Immatics N.V. (IMTX) is facing a liquidity shortage due to extensive R&D spending, necessitating external financing. The current EV/EBITDA multiple valuation demonstrates market resilience, where 0.00 shows the current value of the metric. This is supported by a staff of elite immunologists and the unique XPRESIDENT technology, which guarantees significant pricing power within the inelastic demand segment for cancer therapy.
Summary analytical data breakdowns for immatics.com (IMTX)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Immatics N.V.|IMTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Immatics|IMTX - Company Aggregate Debts|Debt to Book Capitalization Ratio Immatics Biotechnologies|IMTX - Company Long-Term Indebtedness|Company Short-Term Debt Immatics|Quick Liquidity Indicator immatics.com
- financial results and valuation multiples details:
IMTX - Annual Net Income|Future Profit Immatics N.V.|IMTX - Market Price to Net Income Ratio|Forward P/E Multiple Immatics N.V.|IMTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Immatics Biotechnologies|IMTX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Immatics|IMTX - Earnings per share for the trailing year|Quarterly EPS earnings growth immatics.com|IMTX - Earnings growth in current year|Net earnings per share growth forecast for next year Immatics N.V.
Fundamental company analysis:IMTX (Immatics Corp)
Institutional investors are assessing the investment attractiveness of Immatics N.V. (IMTX), considering the risks of international clinical trial disruptions and patent disputes amid geopolitical instability. The current value of 0.00, reflected through the EV/EBITDA multiple, correlates the enterprise value (including net debt) to operating profit, allowing for a determination of the asset's premium relative to industry peers.
Competitor analysis for Immatics N.V.
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Xencor Inc. (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics (CMPX)|Enterprise Value to EBITDA Ratio replimune.com REPL|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Vaccinex Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx
